Objective The aim of this study was to investigate the effect of epidermal growth factor
receptor (EGFR) blockade on cell survival and on downstream signalling pathways using …

Objectives Overexpression or constitutive activation of epidermal growth factor receptors
(EGFR) is involved in growth of human cancers. We investigated effects of EGFR and HER …

The purpose of this study was to assess the effects of the monoclonal antibody cetuximab in
a panel of cultured squamous cell carcinoma cell lines. This antibody, targeting the …

Purpose Predictive strategies for the treatment efficacy of cetuximab are currently not
available for head and neck cancer. We investigated the correlation between the expression …

BACKGROUND: Cetuximab is an epidermal growth factor receptor (EGFR)-blocking
antibody that has been approved for the treatment of patients with head and neck squamous …

Overexpression of the epidermal growth factor receptor (EGFR, ErbB1, HER1) is frequent in
head and neck squamous cell carcinomas (HNSCCs) and correlates with disease …

EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC).
Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation …

The purpose of this study was to evaluate the potency of EGFR pathway inhibition achieved
by combining cetuximab, an anti-EGFR monoclonal antibody, and genistein, a tyrosine …

Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that targets the
extracellular domain of the epidermal growth factor receptor (EGFR) with high specificity and …

Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck
squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance …